Evolus reported break-even to slight profitability in Q2 2026, extending its streak to three consecutive profitable quarters—a meaningful inflection for the Jeuveau manufacturer. Revenue reached $84.08M, up 21% year-over-year, topping analyst expectations. The company raised full-year 2026 guidance on the back of sustained demand for its neuromodulator and growing market share in the toxin category.